Skorpios Trust Amends Stoke Therapeutics Stake

TL;DR

Skorpios Trust just updated its Stoke Therapeutics holdings - big move incoming?

AI Summary

Skorpios Trust, through its filing on April 18, 2024, has amended its Schedule 13D regarding Stoke Therapeutics, Inc. The filing indicates a change in beneficial ownership, with Skorpios Trust now holding a significant stake in the company. The specific percentage and number of shares are detailed within the amendment.

Why It Matters

This amendment signals a potential shift in control or influence over Stoke Therapeutics, which could impact its strategic direction and stock performance.

Risk Assessment

Risk Level: medium — Changes in beneficial ownership filings can indicate activist investor intentions or significant stake-building, which may lead to volatility.

Key Players & Entities

• Skorpios Trust (company) — Filing entity
• Stoke Therapeutics, Inc. (company) — Subject company
• Patrik Blochlinger (person) — Chief Legal Officer of Rigmora (Switzerland) Ltd, related to the filing
• Rigmora (Switzerland) Ltd (company) — Associated entity in the filing

FAQ

Key Financial Figures

• $0.0001 — Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class o
• $11.60 — n open market transaction at a price of $11.60 per share. Item 5. INTEREST IN SECUR

Filing Documents

• stoke13d.htm (SC 13D/A) — 172KB
• 0001123292-24-000113.txt ( ) — 173KB

(b) of this Schedule 13D is hereby

Item 2(b) of this Schedule 13D is hereby amended and restated and Item 2(c) is hereby amended and supplemented as follows: (b) The address of the principal business office of each of Blue Horizon and Ezbon is 3076, Sir Francis Drakes Highway, Road Town, Tortola, British Virgin Island. The address of the principal business office of each of Montrago Trustees and Skorpios Trust is 195 Arch. Makarios III Ave., Neocleous House, 3030 Limassol, Cyprus. (c) The information set forth in amended and restated Annex A hereto is incorporated by reference in response to this item. Item 4. PURPOSE OF TRANSACTION

is hereby amended and supplemented by adding the following

Item 4 is hereby amended and supplemented by adding the following: On April 17, 2024, Ezbon sold 3,600,000 Shares of the Issuer in an open market transaction at a price of $11.60 per share. Item 5. INTEREST IN SECURITIES OF THE ISSUER

(a) – (c) of this Schedule 13D is hereby amended and restated as follows

Item 5(a) – (c) of this Schedule 13D is hereby amended and restated as follows: (a) The responses of the Reporting Persons to rows (7) through (13) of the cover pages of this Schedule 13D are incorporated herein by reference. (b) The responses of the Reporting Persons to rows (7) through (13) of the cover pages of this Schedule 13D are incorporated herein by reference. (c) The information reported in Item 4 is incorporated herein by reference. Other than as disclosed in that item, no transactions in the Shares have been effected by the Reporting Person during the past sixty (60) days. Item 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER

is hereby amended and supplemented by adding the following

Item 6 is hereby amended and supplemented by adding the following: On May 3, 2023, Blue Horizon and Ezbon entered into a Registration Rights Agreement with the Issuer. Pursuant to the Registration Rights Agreement, Blue Horizon and Ezbon are entitled to certain customary rights with respect to the registration of their Shares under the Securities Act of 1933, as amended. As of the date of this filing, neither of Blue Horizon or Ezbon have exercised any registration rights under the Registration Rights Agreement. The Registration Rights Agreement is attached as Exhibit 2 to this Amendment No. 1 and incorporated by reference herein. Item 7. MATERIAL TO BE FILED AS EXHIBITS Exhibit 1 Joint Filing Agreement, dated as of April 18, 2024, by and among the Reporting Persons. Exhibit 2 Registration Rights Agreement, by and among Stoke Therapeutics, Inc., Blue Horizon Enterprise Ltd. and Ezbon International Limited, dated May 3, 2023. (incorporated by reference to Exhibit 4.1 to the Issuer's Quarterly Report on Form 10-Q filed on May 4, 2023).

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of his or its knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct. Date: April 18, 2024 Blue Horizon Enterprise Ltd. By: /s/ Eleni Constantinou Kyriacou Name: Eleni Constantinou Kyriacou Title: Director Ezbon International Limited By: /s/ Eleni Constantinou Kyriacou Name: Eleni Constantinou Kyriacou Title: Director Montrago Trustees Limited By: /s/ Androulla Papadopoulou Name: Androulla Papadopoulou Title: Director Skorpios Trust By: /s/ Androulla Papadopoulou Name: Androulla Papadopoulou Title: Director Exhibit 1 Joint Filing Agreement The undersigned hereby agree as follows: (i) Each of them is individually eligible to use the Schedule 13D to which this Exhibit is attached, and such Schedule 13D is filed on behalf of each of them; and (ii) Each of them is responsible for the timely filing of such Schedule 13D and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate. Date: April 18, 2024 Blue Horizon Enterprise Ltd. By: /s/ Eleni Constantinou Kyriacou Name: Eleni Constantinou Kyriacou Title: Director Ezbon International Limited By: /s/ Eleni Constantinou Kyriacou Name: Eleni Constantinou Kyriacou Title: Director Montrago Trustees Limited By: /s/ Androulla Papadopoulou Name: Androulla Papadopoulou Title: Director Skorpios Trust By: /s/ Androulla Papadopoulou Name: Androulla Papadopoulou Title: Director Annex A Information with respect to Executive Officers and Directors of the Reporting Persons The name and principal occupation of each of the directors and executive officers of Blue Horizo

View Full Filing

View this SC 13D/A filing on SEC EDGAR